Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-13T10:49:24.267Z Has data issue: false hasContentIssue false
  • English
  • Français

Antimicrobial use trends in Canadian adult hematology/oncology inpatient wards: a multi-year exploratory analysis from 2018 to 2023

Published online by Cambridge University Press:  06 April 2026

Claire Moyana,
Annie-Kim NguyenOpen the ORCID record for Annie-Kim Nguyen[Opens in a new window],
John M. Conly,
Daniel J.G. ThirionOpen the ORCID record for Daniel J.G. Thirion[Opens in a new window],
Kevin AfraOpen the ORCID record for Kevin Afra[Opens in a new window],
John Bautista,
Jeannette L. ComeauOpen the ORCID record for Jeannette L. Comeau[Opens in a new window],
Johan Delport,
Yannick Émond and
Gerald A. EvansOpen the ORCID record for Gerald A. Evans[Opens in a new window]
...Show all authors
Claire Moyana
Affiliation:
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
Annie-Kim Nguyen
Affiliation:
Canadian Nosocomial Infection Surveillance Program, Public Health Agency of Canada , Ottawa, Canada
John M. Conly
Affiliation:
Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada
Daniel J.G. Thirion
Affiliation:
Faculty of Pharmacy, Université de Montréal, Montréal, Canada
Kevin Afra
Affiliation:
Department of Medicine, UBC: The University of British Columbia, Vancouver, Canada
John Bautista
Affiliation:
NL Health Services, Grand Falls-Windsor, Canada
Jeannette L. Comeau
Affiliation:
Department of Pediatrics, Dalhousie University, Halifax, Canada
Johan Delport
Affiliation:
London Health Sciences Centre, London, Canada
Yannick Émond
Affiliation:
Faculty of Medicine, Université de Montréal, Montréal, Canada
Gerald A. Evans
Affiliation:
Division of Infectious Diseases, Department of Medicine, Queen’s University, Kingston, Canada
Susan Fryters
Affiliation:
Royal Alexandra Hospital, Alberta Health Services, Edmonton, Canada
Bonita E. Lee
Affiliation:
Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
Xena Li
Affiliation:
North York General Hospital, Toronto, Canada
Darren Pasay
Affiliation:
Pharmacy Services, Alberta Health Services, Vegreville, Canada
Irina Rajakumar
Affiliation:
Pharmacy Services, Alberta Health Services, Calgary, Canada
Mohammed A. Sarhan
Affiliation:
Department of Pathology and Laboratory Medicine, UBC: The University of British Columbia, Vancouver, Canada
Kathryn Slayter
Affiliation:
IWK Health, Halifax, Canada
Alena Tse-Chang
Affiliation:
Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
Olivia Varsaneux
Affiliation:
Canadian Nosocomial Infection Surveillance Program, Public Health Agency of Canada , Ottawa, Canada
Maggie Wong
Affiliation:
Fraser Health, Surrey, Canada
Jessica J. Bartoszko*
Affiliation:
Canadian Nosocomial Infection Surveillance Program, Public Health Agency of Canada , Ottawa, Canada
*
Corresponding author: Jessica J. Bartoszko; Email: jessica.bartoszko@phac-aspc.gc.ca

Abstract

This study explores antimicrobial use (AMU) in a voluntary sample of Canadian adult hematology/oncology wards between 2018 and 2023. Although use of third- and fourth-generation cephalosporins significantly increased, overall AMU decreased by 25%. As trends change over time, ongoing surveillance is needed to guide AMU optimization in this high-risk setting.

Information

Type
Concise Communication
Information
Antimicrobial Stewardship & Healthcare Epidemiology , Volume 6 , Issue 1 , 2026, e90
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Introduction

Antimicrobial use (AMU) and antimicrobial resistance (AMR) pose challenges in hematology/oncology wards. Patients with cancer are highly susceptible to infections due to immunosuppression from malignancy and chemotherapy and face infection-related mortality rates approximately three times higher than those in the general population. Reference Deinhardt-Emmer, Chousterman and Schefold1–Reference Kirk, Pierce and Doll3 Furthermore, they may not exhibit the usual signs of infection and can deteriorate rapidly, warranting empiric broad-spectrum antibiotics in those with febrile neutropenia, which can contribute to increased AMR rates. Reference Deinhardt-Emmer, Chousterman and Schefold1,Reference Kirk, Pierce and Doll3

This exploratory study helps address a gap in AMU and AMR surveillance data by describing AMU trends in a voluntary sample of adult hematology/oncology inpatient wards from hospitals in the Canadian Nosocomial Infection Surveillance Program (CNISP), providing novel benchmark data to inform future surveillance and antimicrobial stewardship (AMS) efforts.

Methods

CNISP is a sentinel surveillance system and a collaborative effort between the Public Health Agency of Canada, the Association of Medical Microbiology and Infectious Disease Canada, and over 110 acute-care hospitals across 10 provinces and one territory. Hospitals that participated in AMU surveillance and submitted AMU data for adult hematology/oncology inpatient wards between 2018 and 2023 were eligible. We included hematology, oncology, bone marrow transplant, and stem cell transplant inpatient wards and compared them to medical and surgical inpatient wards combined. Herein, we refer to these as hematology/oncology and non-hematology/oncology wards, respectively.

Data on systemic antibacterial use, including Anatomical Therapeutic Chemical (ATC) codes J01, P01AB01 (metronidazole oral), and A07AA09 (vancomycin oral), were standardized to defined daily doses (DDDs) using World Health Organization (WHO) ATC/DDD values. DDDs were quantified for adult inpatient surveillance to align with WHO guidelines and allow for comparisons within Canada and internationally. 4 AMU rates were calculated by dividing DDDs by patient days and reported as DDDs per 1,000 patient days (DDD/1000PD). Additional data related to the status and scope of prospective audit and feedback (PAF) and antibiotic preauthorization in eligible hospitals were obtained from a national cross-sectional survey. Reference McGill, Neitzel and Bartoszko5

We reported on the top 10 most used antibiotics in hematology/oncology wards in 2023 and those recommended in clinical practice guidelines. Reference Taplitz, Kennedy and Bow6–Reference Crespo, Forbes and Vu8 We used the Mann-Kendall test to assess AMU rate trends in hematology/oncology wards between 2018 and 2023 and negative binomial regression to evaluate AMU rate differences between hematology/oncology and non-hematology/oncology wards. For the latter, results were reported as incidence rate ratios (IRRs) with 95% confidence intervals (CIs) adjusted for hospital-level clustering. Spearman correlation coefficients were calculated to evaluate the strength of the monotonic relationship between year and AMU rates. All analyses were conducted in R version 4.3.2 at an alpha of .05.

Results

Ten hospitals met eligibility criteria, and those with available data each year ranged from five to nine. Hospital characteristics are reported in the Supplementary File. Briefly, hospitals with 200–500 beds were the most common until 2022 (56% to 83%). In 2023, larger hospitals (>500 beds) were the most common (67%), while teaching hospitals were predominant every year.

Figure 1 presents overall AMU rates by hematology/oncology and non-hematology/oncology wards over time. Between 2018 and 2023, AMU declined by 25% from 850.8 to 638.0 DDD/1000PD in hematology/oncology wards (Mann-Kendall P = .066; rs = −.77, P = .103) and by 4% from 492.2 to 471.8 DDD/1000PD in non-hematology/oncology wards (Mann–Kendall P = .354; rs = −.37, P = .497). In 2023, the AMU rate in hematology/oncology wards was 51% (95% CI 11% to 106%) higher compared to non-hematology/oncology wards (IRR = 1.51, 95% CI: 1.11–2.06).

Figure 1.

Rates of AMU (DDD/1000PD) in adult hematology/oncology and non-hematology/oncology wards (2018–2023). Hematology/oncology wards refer to hematology, oncology, bone marrow transplant, and stem cell transplant inpatient wards. Non-hematology/oncology wards refer to medical and surgical inpatient wards combined. The grey dashed line illustrates the underlying trend in antimicrobial use over time. The slope of this line corresponds to the regression coefficient, indicating the average yearly change.

The Supplementary File provides overall AMU rates in adult hematology/oncology wards by antibiotic class and year. Glycopeptides demonstrated a statistically significant downward trend, while third- and fourth-generation cephalosporins demonstrated a statistically significant upward trend. Rates declined for carbapenems, quinolones, broad-spectrum penicillins, and sulfonamides/trimethoprim, although the trends were not statistically significant. Rates were relatively consistent for macrolides/lincosamides, aminoglycosides, oxazolidinones, and tetracyclines.

Table 1 reports overall AMU rates in adult hematology/oncology wards by antibiotic and year. In 2023, the 10 most frequently used antibiotics were piperacillin/tazobactam, meropenem, vancomycin, ciprofloxacin, ceftriaxone, amoxicillin/clavulanic acid, trimethoprim/sulfamethoxazole, cefazolin, azithromycin, and doxycycline. The ranking of the top five most frequently used antibiotics remained consistent over time. Between 2018 and 2023, there was a statistically significant upward trend in the use of amoxicillin/clavulanic acid and ceftriaxone. An increase was observed for cefazolin; however, there was no statistically significant trend. Rates remained relatively unchanged for doxycycline and azithromycin. While rates declined for ciprofloxacin, meropenem, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole between 2018 and 2023, there was no statistically significant downward trend, unlike for vancomycin. Regarding other clinically relevant agents, a statistically significant downward trend was observed for levofloxacin; however, rates remained relatively unchanged for daptomycin, cefepime, linezolid, tigecycline, and imipenem/cilastatin. The Supplementary File provides a further breakdown by administration route.

Table 1.

Rates of AMU (DDD/1000PD) in adult hematology/oncology wards by antibiotic and year (2018–2023)

* Based on Mann-Kendall trend test.

Of the 10 included hospitals, linked AMS survey data indicated that all 10 reported performing some type of PAF and six reported performing some type of antibiotic preauthorization. The majority (7/10, 70%) reported conducting PAF in hematology/oncology wards specifically, of which 86% (6/7), 100% (7/7), 86% (6/7), 53% (4/7), 71% (5/7), and 86% (6/7) reported PAF for piperacillin/tazobactam, carbapenems, fluoroquinolones, fourth-generation cephalosporins, tigecycline, and daptomycin in these wards, respectively. Half (3/6, 50%) reported performing preauthorization for meropenem, regardless of inpatient ward.

Discussion

This exploratory analysis of a small sample of Canadian adult hematology/oncology wards provides novel data demonstrating a statistically significant upward trend in the use of third- and fourth-generation cephalosporins and a decrease in overall AMU, driven by reduced use of glycopeptides (ie, vancomycin) and, to a lesser extent, carbapenems, quinolones, broad-spectrum penicillins, and sulfonamides/trimethoprim.

In these hematology/oncology wards, lower AMU rates may be attributed to evolving AMS practices and the growing body of evidence around early antibiotic discontinuation. Reference Ishikawa, Masaki, Kawai, Ota and Mori9 Meropenem use decreased by 45.4% from 2018 to 2023, potentially reflecting the impact of targeted stewardship activities (eg, carbapenem PAF), and piperacillin-tazobactam was the most used antibiotic year-over-year, consistent with its role as first-line empiric therapy for febrile neutropenia. Reference Taplitz, Kennedy and Bow7 Our findings align with those from an American academic medical center that evaluated the impact of meropenem preauthorization in hematology/oncology and transplant wards. Between 2012 and 2018, this intervention led to 42.4% reduced meropenem use and 96.2% increased piperacillin-tazobactam use, consistent with clinicians shifting toward narrower-spectrum options. Reference Kirk, Pierce and Doll3

This study has several limitations. Generalizability of the findings to all Canadian acute-care hospitals is uncertain since only 10 hospitals submitted AMU data from hematology/oncology wards. The ward case-mix may also limit generalizability. Only three hospitals provided data for the entire six-year study period. Changes in hospital participation year-to-year, along with pandemic-related disruptions, such as missed cancer workups and reduced hospital admissions, Reference Heer, Ruan and Boyne10 may have skewed temporal trend analyses and led to outliers (eg, tigecycline in 2021). Further, the study period duration may not have been sufficient to capture changes in AMU following AMS interventions, underscoring the importance of continued surveillance. Finally, aggregate ward-level data prevented further study of patient-level AMU indications, antibiotic duration and appropriateness, and clinical outcomes, including treatment failures, to assess whether reductions in AMU have unintended negative consequences.

Nonetheless, these findings may help inform AMS programs monitoring AMU in hematology/oncology wards and provide an initial benchmark for comparison. As trends differ over time and between clinical services, these findings also highlight the need for continued surveillance and targeted AMS efforts to optimize AMU in different settings. Future studies exploring how AMU trends are associated with changes in AMR within CNISP hospitals would be valuable.

Supplementary material

The supplementary material for this article can be found at https://doi.org/10.1017/ash.2026.10359.

Acknowledgements

We gratefully acknowledge the contribution of the staff at each participating hospital and those participating in the Antimicrobial Use Working Group: Kevin Afra, John Bautista, Felix Christen, Jeannette L Comeau, John Conly, Johan Delport, Rita Dhami, Joanne Embree, Yannick Émond, Gerald Evans, Susan Fryters, Jennifer M Grant, Jennifer Happe, Kevin Katz, Joanne M Langley, Jenine Leal, Bonita E Lee, Marie-Astrid Lefebvre, Jerome A Leis, Xena Li, Allison McGeer, Darren Pasay, Irina Rajakumar, Mohammed Sarhan, Michelle Science, Kathy Slayter, Kathryn N Suh, Marty Teltscher, Daniel Thirion, Alena Tse-Chang, Katherine Wang, Karl Weiss, Heather Wise and Maggie Wong.

Author contributions

Conceptualization, CM, AN, JMC, DJGT and JJB; Data Curation, CM, AN, and JJB; Formal Analysis, CM; Methodology, CM, AN, JMC, DJGT and JJB; Writing—Original Draft, CM and JJB; Writing—Review and Editing, CM, AN, JMC, DJGT, KA, JB, JLC, JD, YE, GAE, SF, BEL, XL, DP, IR, MAS, KS, AT, OV, MW and JJB. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Financial support

This work was supported by the Public Health Agency of Canada.

Competing interests

CM was employed by CNISP via the Federal Student Work Experience Program during the conduct of this work. CM received standard student salary support, and manuscript preparation was part of assigned duties. CM reports employment as a medical information resident at Eli Lilly Canada, supporting cardiometabolic health products. This role, by way of CM’s University of Toronto residency, is unrelated to oncology, antimicrobials, or antimicrobial stewardship. Eli Lilly Canada had no role in the design, conduct, analysis, interpretation, or reporting of this study. JMC reports receiving support for travel and attending meetings from the University of Toronto, bioMérieux Canada, and the International Conference on Prevention and Infection Control. JMC reports leadership roles as co-director of the PAHO/WHO Collaborating Centre for Research on Antimicrobial Resistance and the Appropriate Use of Antimicrobials and participation on the PHAC Expert Advisory Group on Antimicrobial Resistance. JMC is a member of the Cochrane Collaboration (Acute Respiratory Infections Group) and works as an infectious diseases consultant at Alberta Health Services, Calgary, Canada. GAE reports participation on the Data Safety Monitoring Board for the IDEA-CRX study. MW received honoraria for a presentation (Canadian Society of Hospital Pharmacists) and lecture (University of British Columbia). JJB declares a previous contract with the World Health Organization and payment from McMaster University for independent methodologist/analyst services rendered.

References

Deinhardt-Emmer, S, Chousterman, BG, Schefold, JC, et al. Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. Lancet Respir Med 2025;13:623–637.10.1016/S2213-2600(25)00124-9CrossRefGoogle ScholarPubMed
Zheng, Y, Chen, Y, Yu, K, et al. Fatal infections among cancer patients: a population-based study in the United States. Infect Dis Ther 2021;10:871–895.10.1007/s40121-021-00433-7CrossRefGoogle ScholarPubMed
Kirk, A, Pierce, J, Doll, M, et al. Effect of carbapenem restriction on prescribing trends for immunocompromised wards at an academic medical center. Am J Infect Control 2019;47:1035–1037.10.1016/j.ajic.2018.12.027CrossRefGoogle Scholar
CNISP Protocols & Publications [Internet]. IPAC-Canada. https://ipac-canada.org/resource-centre/infection-control-resources/cnisp-protocols-publications/. Accessed January 7, 2026.Google Scholar
McGill, E, Neitzel, A, Bartoszko, JJ, et al. Antimicrobial stewardship programs in a network of Canadian acute care hospitals: a cross-sectional survey. Antimicrob Steward Healthc Epidemiol 2025;5:e122.10.1017/ash.2025.181CrossRefGoogle Scholar
Taplitz, RA, Kennedy, EB, Bow, EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 2018;36:3043–3054.10.1200/JCO.18.00374CrossRefGoogle ScholarPubMed
Taplitz, RA, Kennedy, EB, Bow, EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 2018;36:1443–1453.10.1200/JCO.2017.77.6211CrossRefGoogle Scholar
Crespo, A, Forbes, L, Vu, K, et al. Prevention and outpatient management of febrile neutropenia in adult cancer patients: clinical practice guideline. 2021. Cancer Care Ontario. https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/38561. Accessed January 7, 2026.Google Scholar
Ishikawa, K, Masaki, T, Kawai, F, Ota, E, Mori, N. Systematic review of the short-term versus long-term duration of antibiotic management for neutropenic fever in patients with cancer. Cancers (Basel) 2023;15:1611. doi: 10.3390/cancers15051611.CrossRefGoogle ScholarPubMed
Heer, E, Ruan, Y, Boyne, DJ, et al. Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta. CMAJ 2023;195:E804–E812.10.1503/cmaj.221512CrossRefGoogle ScholarPubMed
Figure 0

Figure 1.Rates of AMU (DDD/1000PD) in adult hematology/oncology and non-hematology/oncology wards (2018–2023). Hematology/oncology wards refer to hematology, oncology, bone marrow transplant, and stem cell transplant inpatient wards. Non-hematology/oncology wards refer to medical and surgical inpatient wards combined. The grey dashed line illustrates the underlying trend in antimicrobial use over time. The slope of this line corresponds to the regression coefficient, indicating the average yearly change.

Figure 1

Table 1.Rates of AMU (DDD/1000PD) in adult hematology/oncology wards by antibiotic and year (2018–2023)

Supplementary material: File

Moyana et al. supplementary material

Moyana et al. supplementary material
Download Moyana et al. supplementary material(File)
File 83.6 KB